DOACs in Underweight and Obese Atrial Fibrillation Patients – American College of Cardiology
Geoffrey D. Barnes, MD, MSc, FACC
Related Articles
Genotype-First Approach to Cardiomyopathy Outcomes – American College of Cardiology
Debabrata Mukherjee, MD, FACC
Eagle’s Eye View: Infective Endocarditis After Invasive Dental Procedures, Serious Bleeding in Patients with Atrial Fibrillation (AFib) Using Diltiazem with Apixaban or Rivaroxaban and Low-Dose Colchicine for Secondary Prevention in Atherosclerosis – American College of Cardiology
In this week’s View, Dr. Eagle looks at a systematic review and meta-analysis of antibiotic prophylaxis and infective endocarditis incidence following invasive dental procedures. He…
Bleeding in AF Patients With Diltiazem and DOAC Therapy – American College of Cardiology
Geoffrey D. Barnes, MD, MSc, FACC
SGLT2 Inhibitors and Major Adverse CV Outcomes – American College of Cardiology
Debabrata Mukherjee, MD, FACC
Advocacy at the ACC – American College of Cardiology
The ACC is leading the transformation of care by advocating for a quality driven health care system, provider stability, population health and the future of…
FDA Update: Heartmate II and Heartmate 3 LVAS Recalled Due to Obstruction – American College of Cardiology
The U.S. Food and Drug Administration (FDA) announced on April 15 that Abbott/Thoratec Corp. is recalling the Heartmate II and Heartmate 3 Left Ventricular Assist…
Realizing Our Vision: ACC’s Next 5-Year Strategic Plan
∗Address for correspondence: Ms Cathleen Biga, American Coll ege of Cardiology, 2400 N Street, NW, Washington, DC 20037, USA. E-mail: E-mail Address: [email protected] As…
ACC President Series | Heart-to-Heart – American College of Cardiology
Join ACC President B. Hadley Wilson, MD, FACC (@HadleyWilsonMD), for his new Heart-to-Heart presidential chat series focused on ACC members and their inspiring work to…
Lp(a) and CV Risk Reduction With Icosapent Ethyl – American College of Cardiology
Elizabeth A. Jackson, MD, FACC